NOV Reports Third Quarter 2026 Earnings

NOV reported Q3 2026 revenue of $2.23 billion, up 4% sequentially and 2% year over year. Net income was $90 million, or $0.25 per share, down $22 million sequentially but up $48 million year over year; adjusted EBITDA was $281 million, down $2 million sequentially and up $23 million year over year. Bookings were $577 million, for a 91% book-to-bill ratio. Q3 adjusted EBITDA included approximately $5 million in tariff-refund benefits, compared with approximately $40 million in Q2.

Analysis

The earnings quality is better than the headline sequential EBITDA comparison implies: Q2 included about $40 million of tariff-refund benefit versus only about $5 million in Q3. Given reported EBITDA declined just $2 million, removing those benefits implies underlying EBITDA improved by roughly $33 million sequentially. That supports operating progress despite the modest reported decline; it does not establish that the improvement is durable. The counter-signal is a 91% book-to-bill: if sustained, orders are not replacing current revenue and backlog support could weaken over coming quarters, pressuring NOV’s equipment and services demand. Near term, the market may focus on the sub-1 ratio and lower net income; over 1–3 months, backlog, order mix, and management’s outlook matter more than this quarter’s tariff-adjusted comparison. Over 6–18 months, persistent order weakness would matter more than one quarter of EBITDA progress. Competitors may benefit if NOV’s order weakness reflects share loss, but the excerpt cannot distinguish that from softer end-market demand. Verify the full release for backlog, segment orders, cash flow, and guidance before treating the signal as company-specific.

Key Decisions for Investors

• Do not short solely on the reported $2 million sequential EBITDA decline: the tariff-refund comparison suggests underlying sequential improvement of roughly $33 million. Treat this as a quality-of-earnings adjustment, not proof of a new earnings trend.
• Keep NOV on a watchlist rather than initiate a directional position from this excerpt alone. A pullback could be a long-on-weakness opportunity only if the full release confirms improving underlying segment performance and backlog is stable.
• Use book-to-bill and backlog as the near-term thesis test. Continued sub-1 book-to-bill accompanied by falling backlog or weaker guidance would invalidate the constructive operating read and strengthen a short or underweight case; a recovery above 1 with stable backlog would reduce that risk.
• Before trading, check the share-price reaction and full cash-flow, segment, and guidance disclosures. The excerpt does not establish whether lower net income reflects recurring operating pressure, nor whether weaker bookings indicate share loss or broad customer-capex softness.